Congrats to you! Yes. I loaded up under 8.80. I was hoping to get some in high 7"s but CEMP held up like a rock on the 17th . I have some $ left in case there is a 500 point melt down in the market and CEMP gets in 7"s. I was a bit impatient and bought from 12 all the way down but Im still happy. Im pretty much locked and loaded as TAKSTA phase 111 protocol is any day now and phase 111 genital infection should be announced soon. And who knows…..they could get bought out for $27 at any time.
I hope you got some as did I. Let's see if CEMP runs up into the release of the trial results.
Good and bad in everything. She may have saved a rookie to sell who was in a bad bio, and she enabled me to get a great bio on the cheap in CEMP. Her picking on a sector ( though she said small bio) was a rookie mistake. You know people saw her speech in advance and the bio sector corrected the week before the speech. So now the bio sector is way over sold. Also a concern is I believe Govnt officials can still trade stocks on info they are voting on etc. USA is more like a " Banana Republic" than we know.
The stock drop hurts for longs, but the company still has all the prospects it had before.
Everything I have read so far looks good for Cemp's antibiotic. With such a dire need for new antibiotics, Cemp seems attractively priced down here. Besides, how long will it take for a larger pharma to notice the fire sale price and take an interest. Cemp could be a very attractive takeover candidate. IMHO.
Bought more today. Im locked and loaded. Ok Ms. Fernandes……..you may sell CEMP for $25 a share now.
You found a good one here. There will be volatility until phase 111 is finished. We are only in the 7th inning. CEO stated they are happy with the trial so far and it is 70% complete. That is a nice thing to hear.She also stated the STD trial had 100% recovery which has never happened before as I understand it. A new powerful antibiotic that has a very strong anti-inflammatory composite that doctors will prescribe over those that don't. This will be close to a billion dollar drug. PPS of 9.60 is very cheap for a drug in phase 111 with the data we have imho. Good luck to us all.
added another 500 shares today. Antibiotics has a huge market ! Everyone needs antibiotics for intravenous, oral, and pediatric suspension formulations
I picked up another 1000 shares today. Glad to have the opportunity to buy in the single digits. Very optimistic about solithromycin
Thanks to those on the message board replies and posts. I truly thought that I had a good handle on Cemp's price movement. For sure, the stock market is a humbling experience. I am not selling my shares and will not sell my shares! I do not understand why the stock is selling off as it looked to me we were going much higher. Once again, I think the biotech index ups and downs are selling off all the biotechs, the promising ones as well. I hope this is the case...
Sentiment: Strong Buy
I figure the traders are out from the last upgrade and CEMP bounced of the 50 DMA so I picked up some more today. No hurry to get fully invested here but 8-10 isn't a bad place to add to my position.
Thank you very much for your insights on Solithromycin. I have AKAO on my watchlist as of about a month ago. I appreciate your taking the time to message me. I understand your wanting me to do my own DD. I also say the same when talking about any stock that I like. I believe too that Cempra not only has an intravenous method but then the patient can leave the hospital faster will be able to take an oral dose of Solithromycin.
Sentiment: Strong Buy
Solithromycin against gram positive bacteria is a novel acting macrolide which hits the ribosome at three points meaning effectively there is no resistance seen when using this macrolide. Macrolides command about 10% of all antibiotic sales and Solithromycin is also effective against azithromycin resistance which is the most common macrolide prescribed and does not have some of the side effects seen with azithromycin. Bottom line potential blockbuster.
Tetraphase (TTPH) and also Achaogen (AKAO) are developing novel tetracyclines and aminoglcosides (against gram negative bacteria) respectively which will compete in a space of 5% of the global antibiotic sales. Bottom line perhaps 3-4 increase in current pps and good buy out targets. Disclaimer JMHO please do your own DD.